- Research works
- 4 ▼ 55% vs 2013–17
- Citations
- 92 24.9 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 42% world 28%
Not ranked overall: METAvivor is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does METAvivor publish most on?
By volume in 2022–2025: Cancer Treatment and Pharmacology, Histone Deacetylase Inhibitors Research, Chemotherapy-induced cardiotoxicity and mitigation and Cancer survivorship and care.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Treatment and Pharmacology Oncology 1 works
- 2 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
- 3 Chemotherapy-induced cardiotoxicity and mitigation Cardiology and Cardiovascular Medicine 0 works
- 4 Cancer survivorship and care Oncology 0 works
- 5 Breast Cancer Treatment Studies Cancer Research 0 works
- 6 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
- 7 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 0 works
- 8 Patient-Provider Communication in Healthcare General Health Professions 0 works
- 9 Cardiovascular and Diving-Related Complications Pulmonary and Respiratory Medicine 0 works
- 10 Multiple and Secondary Primary Cancers Epidemiology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has METAvivor's research output changed?
Output in 2018–2022 was 55% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Annapolis
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.